4 Undervalued Biotechnology & Medical Research Stocks for Monday, February 05
Discover the top 4 undervalued Biotechnology & Medical Research stocks for Monday, February 05 based on AAII’s Stock Grades.Grace Malone
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. As of July 21, 2026, Lisata Therapeutics, Inc. operates as a subsidiary of Kuva Labs, Inc.
Commentary & Analysis
Is Lisata Therapeutics Inc (LSTA) Stock a Good Investment?
Learn more about Lisata Therapeutics Inc's (LSTA) stock grades for Value, Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | LSTA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $9.0 | $252.6 | 6% |
|
| Shares Out (Mil) | 9.0 | 52.3 | 19% |
|
| Institutional Ownership | 35.7% | 92.1% | 15% |
|
| Float (Mil) | 7.2 | 40.2 | 16% |
|
| Beta | 0.81 | 0.95 | 48% |
|
| Avg Daily Volume (000s) | 171 | 455 | 43% |
|
| Price Change (52-week) |
(60.9%) | 52.9% | 12% |
|
| Growth | LSTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (15.1%) | (9.9%) | 25% |
|
| EPS (5yr) | 24.8% | 16.0% | 75 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (15.6%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | 2 | 1 | |
| Current EPS | na | ($2.325) | ($1.090) | |
| Month Ago EPS | na | ($2.325) | ($1.090) | |
| # Rev Up | na | 1 | 1 | |
| # Rev Down | na | 0 | 0 | |
| Three Months Ago EPS | na | ($2.325) | ($0.960) | |
| Year/Year Chg | na | 21.8% | (39.2%) | |
| Financials | LSTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $38 | 0% |
|
| Net Income (TTM) (Mil) | ($16) | ($43) | 25% |
|
| EPS (TTM) | ($1.861) | ($1.600) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($14) | ($31) | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $18 | $180 | 10% |
|
| Valuation | LSTA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.83 | 2.56 | 17% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | LSTA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 63.8% | 96% |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (76.0%) | (49.8%) | 7% |
|
| ROE | (90.1%) | (55.5%) | 10% |
|
| Liabilities to Assets | 24.1% | 30.3% | 16% |
|
| F-Score | 1 | 3 | 1% |
|
Passing Stock Screens
As of 7/31/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Schloss Screen
Factors: Value, Quality
This screen looks for stocks hitting new lows, trading at a price lower than book value per share, with no debt and high levels of insider ownership.
| Performance Since Inception: | 0.7% |
| +/- S&P 500: | -6.8 |
